Search

Displaying results 5491 - 5500 of 10000 in total
  1. Drug

    (5Z,7E,9)-decatrien-2-one

    go.drugbank.com/drugs/DB15619
    Investigational

    An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]

  2. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  3. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties … In particular, it is a potent endogenous vasodilator.

  4. Drug

    Mangostin

    go.drugbank.com/drugs/DB14371
    Investigational

    Mangostin is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Pumice

    go.drugbank.com/drugs/DB14374
    Investigational

    Pumice is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. … It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive

  7. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

  8. Drug

    Perenostobart

    go.drugbank.com/drugs/DB18602
    Investigational

    Perenostobart is an alpha-CD39 IgG4 monoclonal antibody.

  9. Drug

    RCT-1213

    go.drugbank.com/drugs/DB32727
    Experimental

    RCT-1213 is an anti-TM4SF5 monoclonal antibody.

  10. Drug

    Vinylglycine

    go.drugbank.com/drugs/DB03214
    Experimental

    Vinylglycine is an irreversible inhibitor of aspartate aminotransferase.